Elicio Therapeutics (ELTX) Non Operating Income (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Non Operating Income came in at -$1.2 million in Q1 2026, down 158.14% YoY from $2.1 million in Q1 2025, and down 208.63% on a QoQ basis from $1.1 million in Q4 2025.
Elicio Therapeutics (ELTX) Non Operating Income (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Non Operating Income data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Non Operating Income fell 158.14% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (up 55.09% YoY) and the FY2025 annual result came in at -$1.9 million, up 73.13% from the prior year.
- Non Operating Income fell to -$1.2 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $3.7 million in Q2 2024 to a low of -$8.5 million in Q3 2024.
- A 5-year average of -$937764.7 and a median of -$473000.0 in 2025 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 1594.95% in 2024, down 15960.0% in 2024.
- Tracing ELTX's Non Operating Income over 5 years: stood at -$4.5 million in 2022, then surged by 109.88% to $443000.0 in 2023, then sank by 219.19% to -$528000.0 in 2024, then soared by 312.88% to $1.1 million in 2025, then tumbled by 208.63% to -$1.2 million in 2026.
- The last three Non Operating Income figures came in at -$1.2 million (Q1 2026), $1.1 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.21 Mn |
| Mar 31, 2026 | -1.22 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -470,000.00 |
| Mar 31, 2025 | -473,000.00 |
| Dec 31, 2024 | -528,000.00 |
| Sep 30, 2024 | -8.49 Mn |
| Jun 30, 2024 | 3.70 Mn |
| Mar 31, 2024 | -1.59 Mn |
| Dec 31, 2023 | 443,000.00 |
| Sep 30, 2023 | 113,000.00 |
| Jun 30, 2023 | 218,000.00 |
| Mar 31, 2023 | 10,000.00 |
| Dec 31, 2022 | -4.49 Mn |
| Sep 30, 2022 | -1.43 Mn |
| Jun 30, 2022 | -1.07 Mn |
| Mar 31, 2022 | 245,000.00 |
| Dec 31, 2021 | 256,000.00 |
| Sep 30, 2021 | 54,000.00 |